[肝段-亚肝段经动脉栓塞化疗对肝功能减退患者肝细胞癌的有效性和安全性]
[Usefulness and safety of segmental-subsegmental TAE for hepatocellular carcinoma in cases of liver hypofunction].
作者信息
Ohno K, Yamada K, Nakamura T, Katsumori T, Sato O, Takahashi T, Fujita M, Maeda T, Kutsumi H, Soga T
机构信息
Department of Radiology, Kyoto 2nd Red cross Hospital.
出版信息
Nihon Igaku Hoshasen Gakkai Zasshi. 1994 Jul 25;54(8):798-800.
We analyzed the safety of the segmental-subsegmental TAE for hepatocellular carcinoma in 18 cases of liver hypofunction by checking total bilirubin change after TAE. The TAE was performed safely in all of the cases. The highest value of total bilirubin before TAE was 5.1 mg/dl in the 1-2 subsegment TAE group, 3.8 mg/dl in the 3-4 subsegment TAE group and 2.0 mg/dl in the 6 subsegment TAE group. We conclude that segmental TAE is safe even in the patient of liver hypofunction.
我们通过检查经动脉栓塞化疗（TAE）后总胆红素的变化，分析了18例肝功能减退患者行节段性-亚节段性TAE治疗肝细胞癌的安全性。所有病例TAE均安全实施。TAE前总胆红素最高值在1-2亚节段TAE组为5.1mg/dl，3-4亚节段TAE组为3.8mg/dl，6亚节段TAE组为2.0mg/dl。我们得出结论，即使是肝功能减退的患者，节段性TAE也是安全的。
Zotero 插件